<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90550">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01691053</url>
  </required_header>
  <id_info>
    <org_study_id>MN0511_1</org_study_id>
    <secondary_id>2011-003179-12</secondary_id>
    <secondary_id>01KG1202</secondary_id>
    <nct_id>NCT01691053</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor Antagonists in End Stage Renal Disease</brief_title>
  <acronym>MiREnDa</acronym>
  <official_title>Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center Wuerzburg (CTCW)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality.
      Cardiovascular (CV) causes account for almost half of all-cause mortality. Increased left
      ventricular mass (LVM) is a common finding in ESRD patients on dialysis and is an
      independent predictor of survival. Yet, to date there is no established medical treatment to
      reduce CV morbidity and mortality in ESRD patients on hemodialysis. Blockade of aldosterone
      action by means of mineralocorticoid receptor antagonists (MRA) provides cardioprotection
      and improves outcome in heart failure patients. Furthermore, the MRA spironolactone has
      recently been shown to reduce LVM in patients with mild-to-moderate chronic kidney disease
      (CKD). The investigators here hypothesize that spironolactone treatment is  cardioprotective
      by reducing LVM in ESRD patients on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Left Ventricular Mass Index</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>as assessed by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac function parameters</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cardiac volumes, systolic and diastolic function, cardiac output as measured by cardiac MRI and echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office and 24h blood pressure</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measures of heart failure severity</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>New York Heart Association (NYHA) functional class, 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Carotid intima meda thickness, pulse wave analysis, carotid artery distensibility, flow mediated dilatation of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of heart failure, inflammation and fibrosis</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and/or hospitalization for heart failure</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pre-dialysis potassium levels, frequency of hyperkalemic episodes (K&gt;6.5mmol/l), measurement of residual kidney function (if applicable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>End Stage Renal Disease / Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>50mg once daily</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Hemodialysis treatment for at least 3 months

          -  At least 3 dialysis sessions per week

          -  Written informed consent

        Exclusion Criteria:

          -  Contraindications for cardiac magnet resonance imaging (CMR)

          -  Mineralocorticoid receptor antagonist treatment within the last 6 months

          -  Estimated life expectancy &lt; 12 months as judged by the nephrologist

          -  History of hyperkalemia, defined as pre-dialysis potassium &gt; 6.5 mmol/l occurring ≥ 3
             times within the last 3 months prior to enrolment.

          -  High risk to develop hyperkalemia defined as pre-dialysis potassium &gt; 6.0 mmol/l

          -  Hypotension (systolic blood pressure &lt; 100 mmHg)

          -  Planned kidney transplantation (living donor) within the prospected study duration

          -  Any acute illness within the last 4 weeks precluding a study participation as judged
             by the nephrologist

          -  Non-amenorrheic women with child bearing potential without reliable contraception,
             pregnancy/lactation

          -  Allergy/hypersensitivity to spironolactone

          -  Non-compliance suspected or demonstrated
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Wuerzburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabian Hammer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Wuerzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabian Hammer, MD, PhD</last_name>
    <phone>+49931201</phone>
    <phone_ext>46380</phone_ext>
    <email>hammer_f@klinik.uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Wanner, MD</last_name>
    <phone>+49931201</phone>
    <phone_ext>39030</phone_ext>
    <email>wanner_c@klinik.uni-wuerzburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Geiger, MD</last_name>
      <phone>+49696301</phone>
      <phone_ext>5555</phone_ext>
      <email>h.geiger@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Betz, MD</last_name>
      <phone>+49696301</phone>
      <phone_ext>7495</phone_ext>
      <email>C.Betz@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Geiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Betz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Aldosterone Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
